Hepatitis Stocks List

Hepatitis Stocks Recent News

Date Stock Title
Jun 10 VKTX Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Jun 9 VKTX This High-Flying Stock Just Announced More Good News: Time to Buy?
Jun 7 VKTX Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors
Jun 7 PLRX Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo
Jun 7 VKTX Viking Therapeutics: MASH Data Punished By Wall Street Amid GLP-1 Uncertainty
Jun 7 AEMD The Hunt for Virus Treatments Continues Post Covid-19
Jun 7 GALT Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges
Jun 7 VKTX Viking Therapeutics (VKTX) Shares Rose in Q1
Jun 6 VKTX Looking At Viking Therapeutics's Recent Unusual Options Activity
Jun 6 AEMD Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Jun 6 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
Jun 6 VKTX Is Viking Therapeutics Stock a Buy on the Dip?
Jun 5 VKTX Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Jun 5 ALGS Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
Jun 4 VKTX Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Jun 4 VKTX Viking falls despite positive mid-stage data for liver drug
Jun 4 ALGS Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
Jun 4 VKTX Viking Therapeutics gains on additional data for NASH drug
Jun 4 VKTX Viking says biopsy data confirm MASH drug’s benefit
Jun 4 GALT Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Hepatitis

Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop yellow discoloration of the skin and whites of the eyes, poor appetite, vomiting, tiredness, abdominal pain, or diarrhea. Hepatitis may be temporary (acute) or long term (chronic) depending on whether it lasts for less than or more than six months. Acute hepatitis can sometimes resolve on its own, progress to chronic hepatitis, or rarely result in acute liver failure. Over time the chronic form may progress to scarring of the liver, liver failure, or liver cancer.The most common cause of hepatitis worldwide is viruses. Other causes include heavy alcohol use, certain medications, toxins, other infections, autoimmune diseases, and non-alcoholic steatohepatitis (NASH). There are five main types of viral hepatitis: type A, B, C, D, and E. Hepatitis A and E are mainly spread by contaminated food and water. Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth. Both hepatitis B and C are commonly spread through infected blood such as may occur during needle sharing by intravenous drug users. Hepatitis D can only infect people already infected with hepatitis B.Hepatitis A, B, and D are preventable with immunization. Medications may be used to treat chronic cases of viral hepatitis. There is no specific treatment for NASH; however, a healthy lifestyle, including physical activity, a healthy diet, and weight loss, is important. Autoimmune hepatitis may be treated with medications to suppress the immune system. A liver transplant may also be an option in certain cases.Worldwide in 2015, hepatitis A occurred in about 114 million people, chronic hepatitis B affected about 343 million people and chronic hepatitis C about 142 million people. In the United States, NASH affects about 11 million people and alcoholic hepatitis affects about 5 million people. Hepatitis results in more than a million deaths a year, most of which occur indirectly from liver scarring or liver cancer. In the United States, hepatitis A is estimated to occur in about 2,500 people a year and results in about 75 deaths. The word is derived from the Greek hêpar (ἧπαρ), meaning "liver", and -itis (-ῖτις), meaning "inflammation".

Browse All Tags